๐
Abecma
idecabtagene vicleucel
Multiple Myeloma
โ
Authorised
Advanced therapy
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/abecma